Illumina, Inc. (NASDAQ:ILMN) SVP Charles Dadswell sold 145 shares of the business’s stock in a transaction dated Tuesday, October 3rd. The shares were sold at an average price of $202.23, for a total value of $29,323.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Charles Dadswell also recently made the following trade(s):

  • On Tuesday, September 5th, Charles Dadswell sold 145 shares of Illumina stock. The shares were sold at an average price of $205.71, for a total value of $29,827.95.
  • On Thursday, August 3rd, Charles Dadswell sold 1,609 shares of Illumina stock. The shares were sold at an average price of $197.00, for a total value of $316,973.00.

Illumina, Inc. (ILMN) opened at 204.18 on Friday. The firm has a 50-day moving average price of $202.57 and a 200 day moving average price of $184.38. The firm has a market capitalization of $29.81 billion, a P/E ratio of 40.97 and a beta of 0.76. Illumina, Inc. has a one year low of $119.37 and a one year high of $214.34.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.14. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The firm had revenue of $662.00 million during the quarter, compared to analyst estimates of $642.38 million. During the same quarter last year, the business posted $0.86 EPS. The company’s revenue was up 10.3% on a year-over-year basis. Equities research analysts anticipate that Illumina, Inc. will post $3.65 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Insider Selling: Illumina, Inc. (ILMN) SVP Sells $29,323.35 in Stock” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/insider-selling-illumina-inc-ilmn-svp-sells-29323-35-in-stock/1617548.html.

Institutional investors have recently bought and sold shares of the stock. Advisory Services Network LLC boosted its stake in Illumina by 13.0% in the 2nd quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock worth $134,000 after purchasing an additional 89 shares during the period. Penserra Capital Management LLC boosted its stake in Illumina by 13.0% in the 2nd quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock worth $153,000 after purchasing an additional 102 shares during the period. Paradigm Asset Management Co. LLC boosted its stake in Illumina by 5.6% in the 2nd quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock worth $165,000 after purchasing an additional 50 shares during the period. Patten Group Inc. boosted its stake in Illumina by 2.7% in the 1st quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock worth $166,000 after purchasing an additional 25 shares during the period. Finally, NN Investment Partners Holdings N.V. boosted its stake in Illumina by 11.3% in the 2nd quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock worth $171,000 after purchasing an additional 100 shares during the period. 93.32% of the stock is owned by hedge funds and other institutional investors.

A number of brokerages have weighed in on ILMN. Argus lifted their price objective on Illumina from $205.00 to $235.00 and gave the company a “buy” rating in a report on Wednesday, September 13th. Leerink Swann reaffirmed an “outperform” rating and issued a $225.00 price objective (up previously from $207.00) on shares of Illumina in a report on Tuesday, September 12th. Vetr raised Illumina from a “hold” rating to a “buy” rating and set a $217.50 price objective on the stock in a report on Tuesday, September 19th. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and issued a $200.00 price objective on shares of Illumina in a report on Tuesday, September 26th. Finally, Zacks Investment Research lowered Illumina from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $183.00.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.